EMEA-001095-PIP02-12

Key facts

Invented name
Tysabri
Active substance
natalizumab
Therapeutic area
Neurology
Decision number
P/0252/2012
PIP number
EMEA-001095-PIP02-12
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of multiple sclerosis
Route(s) of administration
Intravenous use
Contact for public enquiries
Biogen Idec Limited 
Hema.borde@biogenidec.com
United Kingdom 
Tel. +44 1628 512674 
Fax +44 1628 501010
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance procedure number
EMEA-C-001095-PIP02-12
Compliance opinion date
16/12/2016
Compliance outcome
positive

Decision

How useful was this page?

Add your rating